Meclofenoxate

Diseases related to central nervous system injury and cognitive function degeneration have long been a key focus area for clinical medication. As a classic variety of central nervous system stimulant drugs, meclofenoxate mainly promotes the redox metabolism of brain cells, increases glucose utilization, enhances the excitability of central nerve cells, and improves brain function. It is clinically commonly used for the treatment of traumatic coma, alcoholism, neonatal anoxia, childhood enuresis and other conditions, covering the medication needs of multiple departments such as surgery, neurology, pediatrics, etc., and has clear clinical value for patients with central function injury of different age groups.

At present, the domestic market size of meclofenoxate is stable at around 300 million yuan. In recent years, with the increase in diagnosis and treatment demand related to senile cognitive impairment, the market has maintained a low-speed and steady growth of around 4% per year. The competitive landscape is dominated by generic drug enterprises, and no original research product has been marketed and sold in China yet. Preparation manufacturers are concentrated in East China and South China. Domestic enterprises dominate the API supply side, and there is no publicly available statistical data on industry concentration.

The original research of meclofenoxate was developed by Takeda Pharmaceutical Company Limited of Japan, with the original brand name "Lucidril", and the core compound patent has expired globally in the 1970s. The current mainstream dosage forms include capsules (0.1g) and injections (0.25g). The original research related dosage forms are not included in the China Listed Drug Catalogue, and the FDA Reference Listed Drug Catalogue also does not include the original research product of this variety. At present, the meclofenoxate APIs of multiple domestic enterprises have been registered through the CDE, with a total of 8 A-status registration numbers. The corresponding preparation products, namely meclofenoxate hydrochloride capsules and meclofenoxate hydrochloride for injection, have been approved for marketing in China for many years. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of meclofenoxate impurity reference standards. Most products support spot supply. For in-stock products, orders placed before 16:00 can be shipped on the same day. The products meet the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can fully meet the usage needs of different scenarios such as API R&D, quality research, consistency evaluation, etc.